Dataset features

Specifications


Application: RNA-seq analysis
Number of samples: 71
Release date: Nov 1 2018
Last update date: Nov 29 2018
Access: Public
Diseases: Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genes: USP7, NOTCH1, KDM6B
Dataset link USP7 controls the oncogenic transcriptional circuitry and is a novel therapeutic target in T cell leukemia

Experimental Protocol


[USP7 ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against USP7 (Bethyl, A300-033A). [H3K79me2 ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against H3K79me2 (homemade, Ali Shilatifard lab) [H3K27me3 ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against H3K27me3 (Cell Signaling Technology, 9733S). [H2AUb ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against H2AUb (Cell Signaling Technology, 8240S). [H2BUb ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against H2BUb (Cell Signaling Technology, 5546S). [H3K27Ac ChIP]: 10 million cells were used for the ChIP and precipitated using antibody against H3K27Ac (Cell Signaling Technology, 8173S). [RNA-Seq]: 1-5 million primary cells from CUTLL1 human T cell leukemia cells treated with the following inhibitor: 1 micromolar USP7 inhibitor, 1 micromolar GSI, 2 micromolar GSKJ4 and 1 micromolar DMSO. [RNA-Seq]: 1-5 million primary cells from JURKAT human T cell leukemia cells treated with the following inhibitor: 1 micromolar USP7 inhibitor and 1 micromolar DMSO. [RNA-Seq]: 3-5 million primary cells from JURKAT human T cell leukemia cells treated with shUSP7 or empty vector (PLKO). [RNA-Seq]: 1-5 million primary cells from JURKAT human T cell leukemia cells treated with the following inhibitors: 1 micromolar GSI, 500 nanomolar JQ1, and 1 micromolar DMSO.

Repositories


GEO

GSE97435

ENA

SRP103118

BioProject

PRJNA381790

Download


Contact


Panagiotis Ntziachristos